Drugs affecting neurotransmitters Flashcards
1
Q
What is the action of BoTox (Botulinum toxin A)?
A
- modulates release of ACh by blocking vesicular exocytosis
- Tx: wrinkles, dystonia (e.g. blepharospasm/abnormal eye contraction), hyperhydrosis
2
Q
How does BoTox function?
A
- taken up selectively into cholinergic fibres
- light chain acts as a protease to cleave SNARE proteins
- SNARE proteins on the outer synaptic vesicle interact with the neuronal membrane to trigger exocytosis
- tf blocks exocytosis of NT into the synaptic cleft
3
Q
How is AChE modulated?
A
- AChE inhibitors
- false substrates that mimick ACh
- bind to AChE active site, blocking degradation of ACh
- tf ACh acts in synaptic cleft for longer
4
Q
What are the differentiating properties of anticholinesterases?
A
- variable selectivity
- NMJ (somatic) versus parasympathetic junctions
- variable CNS access (many cannot permeate BBB)
- variable duration of action
- short, medium, irreversible
5
Q
Edrophonium
A
- short acting AChE
- used in Dx of myasthenia gravis
6
Q
Neostigmine/Pyridostigmine
A
- reverse effect of neuromuscular blockers
- used in Tx of myasthenia gravis
7
Q
Donepezil
A
- enters CNS
- used in Tx of Alzheimer’s (one of the few)
8
Q
What is myasthenia gravis?
A
- autoimmune disorder
- formation of Abs to own nicotinic receptors
- causes immune response and complement activation at NicRs and their site
- flattens architecture of the NMJ (normally cilia-like)
- cross-linking of 2 AChRs causing them to internalize on the postsynaptic membrane
- [rare] autoAbs prevent ACh binding to NicRs
9
Q
How do anticholinesterases help in myasthenia gravis?
A
- blocks degradation of ACh so there is more in the synaptic cleft to activate the remaining ACh NicRs
- early stage compensation
- long-term lose more receptors and this method is ineffective
- plasmaphoresis to try to remove Ab or immunosuppressive drugs to target underlying cause
10
Q
What is the Tensilon test?
A
- administration of edrophonium, short-acting AChE inhibitor to test myasthenia gravis as a cause of muscle weakness
- if edrophonium relieves weakness, MG is likely cause
11
Q
What are Nm receptors?
A
- peripheral somatic nicotinic receptors
- cause contraction of skeletal muscle
12
Q
What are Nn receptors?
A
- peripheral neuronal nicotinic receptors of the ANS ganglia
- stimulate both ANS branches
13
Q
Nicotinic agonists are not typically used for
A
- peripheral disorders
- can be used for smoking cessation (e.g. patches)
14
Q
What are the clinical uses of nicotinic receptor antagonists?
A
- presurgical skeletal muscle relaxants (Nm selective)
- e.g. non-depolarising forms tubocurarine/vecuronium
- ANS ganglion blockers (Nn selective) - rare and limited use
- e.g. hexamethonium
15
Q
Agonist stimulation of ANS muscarinic receptors yields
A
-
SLUD:
- Salivation, Lacrimation, Urination, Defecation
- sweating
- bradycardia
- bronchoconstriction
- vasodilation (non-neural)